Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 185Neoplasms 181Carcinoma, Non-Small-Cell Lung 153Prostatic Neoplasms 120Colorectal Neoplasms 111Lung Neoplasms 97Ovarian Neoplasms 83Neoplasm Metastasis 82Multiple Myeloma 76Pancreatic Neoplasms 75Leukemia, Myeloid, Acute 65Endometrial Neoplasms 52Stomach Neoplasms 48Squamous Cell Carcinoma of Head and Neck 47Melanoma 47Recurrence 46Lymphoma 45Hematologic Neoplasms 44Glioblastoma 44Carcinoma, Renal Cell 44Brain Neoplasms 44Carcinoma, Hepatocellular 42Urinary Bladder Neoplasms 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Lymphoma, Non-Hodgkin 39Leukemia, Lymphocytic, Chronic, B-Cell 38Triple Negative Breast Neoplasms 35Glioma 35Small Cell Lung Carcinoma 34Sarcoma 34

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Primary Malignant Peripheral Nerve Sheath Tumors × 30 days × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡